Literature DB >> 10755391

The antimitotic effects of Ukrain, a Chelidonium majus alkaloid derivative, are reversible in vitro.

A Panzer1, A M Joubert, P C Bianchi, J C Seegers.   

Abstract

Ukrain is alleged to be an effective chemotherapeutic drug which causes minimal side-effects as a result of selective toxicity towards malignant cells only. We previously failed to confirm this claim and found Ukrain to be equally toxic to normal, transformed and malignant cell lines by causing a metaphase arrest. In this study we have found the antimitotic actions of Ukrain to be reversible in low doses in vitro, as shown by flow cytometry and concurrent haematoxylin and eosin stains. We hypothesize that the lack of side-effects found in vivo may be due to the lack of therapeutically effective dosages being administered, therefore enabling cells to overcome the metaphase arrest and survive.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755391     DOI: 10.1016/s0304-3835(99)00375-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Activity of the chelerythrine, a quaternary benzo[c]phenanthridine alkaloid from Chelidonium majus L. on Dactylogyrus intermedius.

Authors:  Xi-Lian Li; Jia-Yun Yao; Zhi-Ming Zhou; Jin-Yu Shen; Hong-Shun Ru; Xiao-Lin Liu
Journal:  Parasitol Res       Date:  2011-03-12       Impact factor: 2.289

2.  Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonine.

Authors:  Sakineh Kazemi Noureini; Michael Wink
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

Review 3.  Ukrain - a new cancer cure? A systematic review of randomised clinical trials.

Authors:  E Ernst; K Schmidt
Journal:  BMC Cancer       Date:  2005-07-01       Impact factor: 4.430

Review 4.  Greater Celandine's Ups and Downs-21 Centuries of Medicinal Uses of Chelidonium majus From the Viewpoint of Today's Pharmacology.

Authors:  Sylwia Zielińska; Anna Jezierska-Domaradzka; Magdalena Wójciak-Kosior; Ireneusz Sowa; Adam Junka; Adam M Matkowski
Journal:  Front Pharmacol       Date:  2018-04-11       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.